Neurocrine Biosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Neurocrine Biosciences yıllık ortalama 12.2% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.1% annual. Gelirler growing yılda ortalama 21% oranında artmaktadır. Neurocrine Biosciences'in özkaynak karlılığı 14.2% ve net marjı 17.2%'dir.

Anahtar bilgiler

12.2%

Kazanç büyüme oranı

10.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	21.0%
Özkaynak getirisi	14.2%
Net Marj	17.2%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

Recent updates

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Oct 10

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Jul 09

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

May 08

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Apr 27

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Apr 25

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Mar 31

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

Feb 11

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Jan 07

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Dec 11

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Sep 12

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Jun 08

Gelir ve Gider Dağılımı

Neurocrine Biosciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:NBIX Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	2,243	386	924	0
30 Jun 24	2,120	339	908	0
31 Mar 24	1,982	370	888	0
31 Dec 23	1,887	250	888	0
30 Sep 23	1,784	191	852	0
30 Jun 23	1,673	176	834	0
31 Mar 23	1,599	64	795	0
31 Dec 22	1,489	155	753	0
30 Sep 22	1,389	58	726	0
30 Jun 22	1,297	12	695	0
31 Mar 22	1,208	71	655	0
31 Dec 21	1,134	90	583	0
30 Sep 21	1,069	445	533	0
30 Jun 21	1,032	365	491	0
31 Mar 21	1,045	402	445	0
31 Dec 20	1,046	407	433	0
30 Sep 20	1,042	93	428	0
30 Jun 20	1,006	205	400	0
31 Mar 20	887	177	384	0
31 Dec 19	788	37	354	0
30 Sep 19	675	21	322	0
30 Jun 19	605	18	298	0
31 Mar 19	519	-39	278	0
31 Dec 18	451	21	249	0
30 Sep 18	414	10	236	17
30 Jun 18	323	-52	220	32
31 Mar 18	233	-106	200	48
31 Dec 17	162	-143	170	0
30 Sep 17	67	-194	137	90
30 Jun 17	6	-220	111	88
31 Mar 17	0	-200	84	90
31 Dec 16	15	-141	68	58
30 Sep 16	15	-126	53	57
30 Jun 16	15	-123	47	58
31 Mar 16	15	-107	39	52
31 Dec 15	20	-89	32	48
30 Sep 15	20	-79	29	44
30 Jun 15	20	-60	22	37
31 Mar 15	20	-50	19	34
31 Dec 14	0	-61	18	32
30 Sep 14	1	-52	16	29
30 Jun 14	1	-47	15	27
31 Mar 14	2	-46	14	26
31 Dec 13	3	-46	13	25

Kaliteli Kazançlar: NBIX büyük bir tek seferlik zarar ile $168.1M, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: NBIX 'nin mevcut net kar marjları (17.2%) geçen yılın (10.7%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: NBIX şirketinin kazancı son 5 yılda yılda 12.2% oranında arttı.

Büyüme Hızlandırma: NBIX 'un son bir yıldaki kazanç büyümesi ( 102% ) 5 yıllık ortalamasını (yıllık 12.2% ) aşıyor.

Kazançlar vs. Sektör: NBIX geçen yılki kazanç büyümesi ( 102% ) Biotechs sektörünün 16.6% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: NBIX 'nin Özsermaye Getirisi ( 14.2% ) düşük olarak değerlendiriliyor.

Neurocrine Biosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Recent updates

Chief Medical Officer exercised options to buy US$903k worth of stock.

Neurocrine Biosciences, Inc. Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents Breadth of Data Demonstrating Holistic Improvements over Time in Patients with Tardive Dyskinesia Following Treatment with INGREZZA (Valbenazine) Capsules

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $300 million worth of its shares.

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)

Neurocrine Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

The Play On Neurocrine Biosciences

Chief Corporate Affairs Officer notifies of intention to sell stock

Chief Corporate Affairs Officer notifies of intention to sell stock

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Investor sentiment deteriorates as stock falls 18%

Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data

Price target increased by 7.0% to US$172

Independent Chairman of the Board recently sold US$2.1m worth of stock

Independent Director exercised options and sold US$1.2m worth of stock

Chief Human Resources Officer exercised options and sold US$1.2m worth of stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. Launches INGreZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Independent Director notifies of intention to sell stock

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Chief Financial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Consensus EPS estimates fall by 12%

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

Insufficient new directors

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Independent Director notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Insider notifies of intention to sell stock

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Insider notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Insider notifies of intention to sell stock

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023